Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.
- Judy S. Wang
- , David Sommerhalder
- , Manish Sharma
- , William Jeffery Edenfield
- , Kartik Sehgal
- , Do Youn Oh
- , Yixing Jiang
- , Joel Michalski
- , Jeeyun Lee
- , Hans J. Hammers
- , Li Yuan Bai
- , Chih Hung Hsu
- , Brenda A.P. Dampier
- , Kefei Zhou
- , Lisa K. Blum
- , Joanne Sloan Lancaster
- , Dhiraj J. Abhyankar
- , Hsiao D. Lieu
- , Vladimir Hanes
- , Aung Naing
- Sarah Cannon Research Institute/Florida Cancer Specialists
- NEXT Oncology
- START Midwest
- Prisma Health Cancer Institute
- Dana-Farber Cancer Institute
- Seoul National University
- University of Maryland, Baltimore
- Nebraska Cancer Specialists
- University of Texas Southwestern Medical Center
- China Medical University Taichung
- National Taiwan University
- NGM Biopharmaceuticals, Inc.
- University of Texas MD Anderson Cancer Center
Research output: Contribution to journal › Article › peer-review
6
Link opens in a new tab
Scopus
citations